DESCRIPTION (provided by applicant): During epithelial maturation, a large number of signal transduction molecules are utilized to regulate cell cycle and cell death. When activated by mutation these same factors can provoke uncontrolled growth, a common step in the development of cancer. For example, activating mutations in the Ret receptor tyrosine kinase can provoke oncogenic diseases such as Multiple Endocrine Neoplasia Type 2 (MEN2). By targeting analogous forms of activated Ret to the developing Drosophila retina, an in vivo model was developed to explore the downstream signaling components that are responsible for aspects of the MEN2 disease. This approach identified several pathways that, when mutated, alter the outcome of Ret activation. The importance of these pathways in human tumor tissue is currently being explored.
One downstream pathway that modified the Ret (MEN2) phenotype was the Src signaling pathway. Src is a cytoplasmic kinase that has been linked to dozens of cancer types including those of the colon and breast, as well as blood-based cancers. C-terminal Src kinase (Csk) is the major inhibitor of Src signaling. Reducing Drosophila Csk activity led to activation of Src and a concomitant cell-autonomous activation of the cell cycle, which in turn led to uncontrolled growth. The result was an enlarged, abnormally patterned eye. Importantly, reducing activity of the STAT signaling pathway prevented this oncogenic growth: mutations in Drosophila STAT led to death of otherwise proliferative Csk tissue. This suggests a strategy for therapeutic intervention of tumors that contain an activated Src pathway.
This Proposal seeks to better understand the nature of STAT's ability to kill Csk-deficient cells by using genetic screens to identify 'killing' pathways. In addition, the role of Src signaling downstream of a number of receptors will be further explored. Finally, the advantages of the Drosophila retina as a sensitive assay of signaling, overgrowth, and cell death will be exploited as an in vivo screen for drugs that can also ameliorate Csk/Src-mediated overgrowth.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Drosophilidaeapoptosisbiological modelsbiological signal transductioncell cycleenzyme activitygenetic screeningmodel design /developmentmultiple endocrine neoplasianeoplasm /cancer geneticsneoplastic processpolymerase chain reactionprotooncogeneterminal nick end labeling
No Sub Projects information available for 1R01CA109730-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01CA109730-01
Patents
No Patents information available for 1R01CA109730-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01CA109730-01
Clinical Studies
No Clinical Studies information available for 1R01CA109730-01
News and More
Related News Releases
No news release information available for 1R01CA109730-01
History
No Historical information available for 1R01CA109730-01
Similar Projects
No Similar Projects information available for 1R01CA109730-01